Objective: To determine the song -term safety and effectiveness of risperidone for severe disruptive behaviors in children. Method: A multisite, 1 -year, open -label study of patients aged 5 ìo 14 years with disruptive behaviors and subaverage intelligence was cònducted. Results: Seventy -three percent of the 504 patients enrolled completed the study. The mean ± SE dose of risperidone was 1.6 a 0.0 mg /day. The most common ad.r rse events were somnolence (30 %), rhinitis (27 %), and headache (22 %). The incidence of movement disorders was low, and mean Extrapyramidal 
The prevalence of conduct disorder in children and adolescents appears to have increased over the past decades, with general population studies reporting rates ranging from less than 1% to more than 10% and a higher incidence in boys thou girls (American Psychiatric Association, 2000). Although they can occur in children and adolescents with normal intelligence, disruptive behavior disorders are more commouly associated with below-average intelligence quotients (Campbell and Malone, 1991) .
The consequences of disturbed behaviors for the patients and their families are profoúnd and have serious implications for society. Hechturan and Offord (1994) have observed that conduct disorders of early childhood are predictive of "widespread social malfunction, as seen in high rates of divorce and separation, poor work history, and unsatisfactory social relationships." j. AM. ACAD. CHILD ADOLESC. PSYCHIATRY 
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Antipsychotics have been used to treat disruptive behavior disorders in children for more than 20 years (Bennett et at, 1983; Campbell et al., 1984; Greenhill et al., 1985) despite limited data on their short-and long -term efficacy and safety. A significant disadvantage of conventional antipsychotics, particulady in children, is their association with adverse events, including photosensitivity (phenothiazines), galactorrhea (thioridazine), cardiotoxicity (pimozide), sedation and drooling (molindone, haloperidol), cognitive dulling (haIoperidoI), and the more familiar movement disorders, such as extrapyramidal symptoms (EPS) and tardive dyskinesia (Santosh and Baird, 1999; Silva et al., 1996) .
The benefits of risperidone in the short-term treatment of disruptive behavior disorders are well documented. 1111993, Vanden Borre et al. (1993) demonstrated in a double -blind, placebo -controlled trial that adjunctive risperidone was well tolerated and significantly better than placebo in treating mentally retarded adults with persistent behavioral disturbances.
This report was followed by more than a dozen promising open -label studies and case reports of risperidone used alone or as an adjunctive treatment in adults, adolescents, and children with severe behavior problems. Three double -blind, placebo -controlled pilot studies involving children and adolescents with disruptive behavior disorders were also conducted and demonstrated that risperidone monotherapy was significantly more effective than placebo (Buitelaar et al., 2001; Findling et at, 2000; Van Bellinghen and De Troth, 2001 ). These findings have been confirmed in two large randomized, multicenter, double-blind, placebo-controlled studies of very disruptive children with subaverage intelligence . (Aman et al., 1985) , and Clinical GIobal Impressions (CGI) Scale (Guy, 1976) . Por each child, the most troublesome symptom was identified by the parent or caregiver and scored using a visual analog scale. The parent or caregiver also completed the 'Child Symptom Inventory (Gadow and Sprafldn, 1994) , a srandarrli,rd informant scale used to assess all majorDSM-.1V conditions in children. After the parent or caregiver completed the N -CBRF, Child Symptom Inventory, visual analog scale, and Aberrant Behavior Cheddist, the clinician recorded medical and psychiatric histories, examined the child, and completed the Extrapyramidal Symptom Raring Scale (ESRS) (Chon; nard et al, 1980) and CGI Scale. Based on this information, the investgator made a DS111 IV diagnosis. The intelligence of each child was assessed using the Stanford -Binet Intelligence Scale (Thomdike et al., 1986) or the WISC third edition (Wechsler, 1974 (Sparrow et aL, 1984 Psychotropic medications other than risperidone were not permitted with the following exceptions: Psychosimulants were allowed for attention-deficit/hyperactivity disorder provided the patient had been stabilized on a constant dose for 30 days before entering the trial, sedatives or hypnotics were allowed for sleep if the patient had been receiving these mediations before the screening visir, and benzodiazepines were allowed as premedication for medical procedures. No medications for sleep or anxiety were to be started during the mat Medications used for EPS had to be discontinued at study entry. If EPS emerged during the trial, andchol;nergic drug therapy could be considered if dose reduction of the study medication was unsuccessful. Behavioral therapy was permitted if it was initiated at least 30 days before the gran of the study. No changes in psychosrimulant use or behavioral therapy were allowed during the study.
Assessments
After screening, visits were scheduled at baseline (=anew initiation), days 7, 14, 21, and 28, and months 2 to 6, 9, and 12. Adverse events were recorded throughout the treatment period. Vital signs were" assessed at each visit, and a complete physical examination, including height measurement, was performed at screening and months 1, 3. 6, and 12. We evaluated EPS severity at all time points ',sing the ESRS. Weight measurements, clinical laboratory tests, and electrocardiography were performed at screening and months 1, 3, 6, and 12. Sexual maturation was evaluated by means of Tanner stagging at baseline and months 6 and 12. Venous blood samples for pharmacokinetic analysis for risperidone and the active moiety (risperidone plus 9-hydroxyiisperidone) were taken at screening and at trough level (i.e., just before the rtes.-, scheduled drug intake or 24 hours after the last drug dose) at week 4 and months G and 12.
We assessed cognitive function at baseline and months 6 and 12 using a modification of the children's version of the California 
Data Analysis
We assessed safety in all patients who entered the trial and tabulated all adverse events by type and incidence. The Wilcoxon signed rank test (two sided) was used to evaluate changes from baseline in ESRS scores (Lehmann, 1998) . Changes from baseline for all other safety measres were evaluated sting two -sided paired r tests. Preand posttreatment clinical laboratory data frequencies were calculated, including those for important abnormalities.
Effectiveness was assessed in all patients who received at least one dose of risperidone during the trial and for whom data on the Conduct Problem Subscale of the N-CBRF were available. Changes in scores from baseline to end point (the last observation for each patient) or other time points for the N -CBRF, CGI, and Aberrant Behavior Checklist were analyzed using two-sided paired t rests.
Because of m;esing assessments at particular visits, mean scores and changes versus baseline may be based on a different number of observations. Because most of the N -CBRF and Aberrant Behavior Checklist assessments were complete, we did nor impute missing items to calculate subscale scores. However, when one or more items were missing, the score of the subscale was set to missing.
Mean The most common additional medications used during the trial were analgesics, antibiotics, and psychostimulants. Concomitant medications taken by Z5 %. of patients included paracetamol (27% of padents), amoxicillin (14 %), methylphenidate or methylphenidate hydrochloride (14 %), sulfamethoxazole/trimethoprim (5 %), ibuprofen (5 %), and aspirin (5 %).
Safety
Adverse events were generally mild or moderate, the most-common being somnolence -(3O% òf p-aiEnts), rhinitis (27 %), and heads the (22 %) ( Table 2) . Adverse events resulting in withdrawal from the study by three or more of the 504 patients included weight gain (nine patients), increased appetite (four patients), gynecomastia (three patients), somnolence (three patients), and headache (three patients).
Severity of EPS was low at baseline (mean ESRS total score, 1.2 ± 0.1) and decreased at each assessment thereafter. The mean ESRS total score changes from baseline were -0.4 ± 0.2 at month 12 {p < .001) and -0.3 ± 0.1 at end point (p = .024, Wilcoxon signed rank test). Five patients (1 %) required antiparkinsonian medications during the study, and in six patients (1 %), EPS led to discontinuation. Two patients devel- then decreased CO 16.1 ± 11.9 and 21.6 ± 22.0 ng /mL, respectively, at end point (upper Iimits of normal are 18 ng /mL for boys and 25 ng /mL for girls) (Fig. 1) chan scores at end point were as follows: total long delay -free recll, 0.7 ± 0.1; total short delay -free recall, 2.9 ± 0.4; and total correct, 0.7 ± 0.2 (each p < .001 versus baseline by two-sided paired t test), On the Continuous Performance Task easy and hard tests, the number of correct responses increased and the number of errors decreased. Mean change scores at end point were as follows: total hits, 1.6 ± 0.3 and 1.6 ± 0.4, respectively; total false alarms, -2.9 t 0.6 and -4.2 ± 0.7, respectively, and total misses, -1.5 ± 0,3 and J. AM. ACAD. CHILD ADOLF-SC. PSYCHLATRY, 44:7, JANUARY 2005 JJRE 03849816 Confidential /Produced in Litigation Pursuant to Protective Order -1.4 ± 0.4, respectively (each p < .001 vs. baseline by two -sided paired t test).
Effectiveness
Significant improvement was noted at each time point after baseline on the primary measure of effectiveness, the N -CBRF conduct probI"em subscale (Table 3 ). The mean score decreased from 32.9 ± 7.5 at the open -Iabel baseline to 17.0 ± 11.0 at end point The mean change at end point was -15.8 ± 0.5 (p < .001). This represents a 48% decrease in the mean score. Considerable improvements were seen from weeks 1 to 4, and the improvements were mainrained during the subsequent 11 months.
Significant improvements were also seen on the positive social behavior and problem behavior N -CBRF subscales (Fig. 2) . Compliant/calm and adaptive/social both increased significantly (p < .001), with mean changes of 3.4 ± 0.12 and 1.9 ± 0.13, respectively.
Insecure/anxious, hyperactive, self -injury/stereotypic, self-isolated/ritualistic, and overly sensitive subscale scores all decreased significandy (p < .001), with mean changes of -5.4 ± 0.4, -6.8 ± 0.3, -1.0 ± 0.2, -1.7 ± 0.02, and -2J ± 0.02, respectively.
On the CGI Severity Scale at baseline, 72% of patients had marked to extremely severe symptoms. At end point, 12% had marked to extremely severe symptoms and 66% were rayed as not iII or having mild symptoms. Mean Aberrant Behavior Checklist total scores decreased from 643 ± 25.0 at baseline to 37.4 ± boys (Glass, 1994) and girls ( Findling et al., 2003 ), so it is not possible to assess the contribution of risperidone without a placebo control group.
Both the 48 week trial of risperidone in children (Findling et al., 2004) and an analysis of combined data from Iong -term trials of risperidone in children and adolescents (Findling et al., 2003) (Dunbar et aL, 2004) .
Results of two landmark short -term (6-week), double -blind, placebo -controlled studies of risperidone in children with disruptive behavior disorders have recently been published Snyder er al., 70 2002 Findling et al. (2000) indicated that risperidone is effective in children with conduct disorder and normal intelligence. Finally, we focused on children with severe disruptive behaviors. Unlike disorders such as adult schizophrenia, we do not yet know whether long -term treatment of disruptive behaviors in children is useful in all patients. However, in a study of adolescents given risperidone for aggression, Buitelaar et al. (2601) observed deterioration in the 2 -week washout phase that followed his 6 -week, double -blind treatment period. Their data suggest that, at Ieast in patients with the most severe problems, symptoms rend to return when treatment is stopped and therefore that some patients will benefit from longtenu treamient. 
